cere-120
Gene therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2005 (NCT00252850)
Timeline
Indications
Studied for
Mechanism of action
- NeurturinSupplementation
NRTN supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cere-120
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00985517 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2009 | Ceregene, Sangamo BioSciences |
| NCT00400634 | Phase 2 | Nov 1, 2006 | Ceregene |
| NCT00252850 | Phase 1 | Jun 1, 2005 | Ceregene, Rush University, University of California, San Francisco |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ceregene | For profit | 3 | 2 | 2 | 2005 |
| Rush University | Academic/Hospital | 1 | 0 | 1 | 2005 |
| Sangamo BioSciences | For profit | 1 | 1 | 1 | 2009 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2005 |
4 organizations
Page 1 / 1